Moedling, Austria

Xaver Koenig

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 14(Granted Patents)


Location History:

  • Vienna, AT (2016)
  • Moedling, AT (2015 - 2018)

Company Filing History:


Years Active: 2015-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Xaver Koenig: Innovator in Medical Treatments

Introduction

Xaver Koenig is a notable inventor based in Moedling, Austria. He has made significant contributions to the field of medical treatments, particularly in the area of cystic fibrosis and cell differentiation. With a total of four patents to his name, Koenig's work reflects a commitment to advancing healthcare solutions.

Latest Patents

Among his latest patents is a composition for the treatment of cystic fibrosis. This invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof, for use in preventing or treating cystic fibrosis. Additionally, he has developed a method involving triazine derivatives as differentiation catalysts. This method induces the differentiation of mammalian cells into cardiomyocyte-like cells by utilizing specific triazine compounds.

Career Highlights

Throughout his career, Xaver Koenig has worked with reputable organizations such as Scipharm Sarl and Technische Universitaet Wien. His experience in these institutions has allowed him to refine his expertise and contribute to innovative research in medical science.

Collaborations

Koenig has collaborated with esteemed colleagues, including Michael Freissmuth and Marko Mihovilovic. These partnerships have further enhanced his research and development efforts in the medical field.

Conclusion

Xaver Koenig's contributions to medical innovations, particularly in cystic fibrosis treatment and cell differentiation, highlight his role as a significant inventor. His work continues to inspire advancements in healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…